飞利浦二季度销售增长但利润改善主要来自一次性关税退款，订单与中国市场承压

S. Korea stocks slump over 10% as AI spending fears hammer chip stocks
Introduction & Market Context
Royal Philips (NYSE:PHG) presented its second-quarter 2026 results on July 28, 2026, highlighting 4% comparable sales growth and a raised full-year outlook driven by a significant U.S. tariff refund. However, the presentation’s positive messaging contrasted sharply with market reaction, as shares fell 4.39% during the regular session to $25.02 and declined another 3.04% after-hours to $24.26, trading near the bottom of the 52-week range of $24.82 to $33.44.
The disconnect between operational achievements and investor sentiment underscores ongoing concerns about underlying margin pressure, cost inflation running at high-single-digit rates, and persistent weakness in China’s centralized procurement environment. While CEO Roy Jakobs and CFO Charlotte Hanneman emphasized disciplined execution and commercial momentum, the market focused on a cautionary Q3 outlook and the temporary nature of the tariff benefit.
Quarterly Performance Highlights
As shown in the following summary of key financial metrics, Philips delivered growth across all three business segments in the second quarter, though profitability gains were heavily influenced by a one-time benefit.
The company reported comparable sales growth of 4% in Q2 2026, maintaining the same pace achieved in the first half of the year. Adjusted EBITA margin reached 16.4%, representing a 400 basis point expansion year-over-year. However, this headline figure included approximately 420 basis points of benefit from a U.S. tariff refund. Excluding this one-time gain, the underlying adjusted EBITA margin declined 20 basis points to 12.2%, reflecting the impact of higher tariffs and cost inflation that more than offset productivity improvements.
The company’s productivity initiatives delivered EUR 132 million in savings during the quarter, bringing first-half savings to EUR 258 million as part of a EUR 1.5 billion program spanning 2026-2028. Free cash flow of EUR 222 million remained broadly in line with the prior year, as higher working capital outflows were largely offset by the tariff refund. The leverage ratio improved from 2.2x to 1.8x on a net debt to adjusted EBITDA basis.
The following chart illustrates commercial momentum through equipment order intake trends and order book development over the past five quarters.
Equipment order intake showed a 1% decline in the quarter but maintained 5% growth on a rolling twelve-month basis. The Diagnosis & Treatment segment delivered resilient low-single-digit order growth driven by recent innovations, while Connected Care experienced a mid-single-digit decline primarily reflecting the timing of larger orders between quarters. Importantly, the order book remained at record levels and accounts for approximately 40% of revenue, providing visibility into future sales conversion.
Regional demand patterns varied significantly across Philips’ portfolio. The following breakdown shows how hospital demand and consumer sentiment evolved across key markets.
North America demonstrated strong hospital demand driven by productivity improvements, patient volume growth, and health system financial improvement, though consumer sentiment remained measured. Europe showed strength across both hospital and consumer segments, supported by productivity and digitalization initiatives. Greater China faced headwinds from centralized procurement expansion and subdued consumer sentiment, despite government stimulus efforts. The rest of world markets delivered solid to strong performance, benefiting from infrastructure investments and digitalization trends.
Segment Performance Analysis
Diagnosis & Treatment
The Diagnosis & Treatment segment, which includes imaging systems and image-guided therapy solutions, generated sales of EUR 2,085 million with 2% comparable growth, recovering from a 1% decline in the prior-year quarter.
The segment’s adjusted EBITA margin reached 13.9%, up from 13.5% in Q2 2025. However, excluding the U.S. tariff refund benefit, the underlying margin stood at 9.3%, reflecting significant pressure from cost inflation, higher tariffs, and currency effects that more than offset productivity measures. Image Guided Therapy delivered high-single-digit growth driven by strength in Europe and North America, while Precision Diagnosis experienced a low-single-digit decline primarily due to continued pressure in China.
The segment’s strategic positioning benefited from major partnership announcements and innovation launches. As illustrated in the following overview of strategic initiatives:
Philips signed an agreement for 14 catheterization labs with one of the largest nonprofit healthcare organizations in the U.S., supporting advanced minimally invasive procedures. The company is also modernizing more than 200 hospitals in Poland through large-scale deployment of imaging, image-guided therapy, ultrasound, and patient monitoring solutions. A landmark strategic alliance with WellSpan will co-develop and validate AI-enabled technologies, building on a long-term commercial agreement making Philips the preferred vendor across multiple modalities.
Recent product innovations driving order intake included the Verida CT and Rembra CT systems, both recently approved by China’s National Medical Products Administration, along with helium-free MR systems and the Ultrasound Flash 5100 point-of-care device. The following showcase of advanced technologies demonstrates the breadth of Philips’ innovation pipeline:
Key innovations included Smart IQ for Azurion, which advances coronary image quality while using over 50% less X-ray radiation than current low-dose settings; Elevate Plus, an AI-powered imaging and automation solution for flagship ultrasound systems that received FDA 510(k) clearance and CE marking; 4D MR-RT, the first-of-its-kind multi-contrast 4D MR imaging solution for radiotherapy simulation; and the next-generation Titanion 3.0T MRI system designed to advance quantitative imaging beyond anatomical and functional applications.
Connected Care
The Connected Care segment, encompassing patient monitoring, sleep and respiratory care, and enterprise informatics solutions, reported sales of EUR 1,184 million with 2% comparable growth, also recovering from a 1% decline in the prior year.
Connected Care’s adjusted EBITA margin reached 17.8%, significantly up from 10.4% in Q2 2025, though the underlying margin excluding the tariff refund stood at 11.7%. The segment achieved margin expansion as productivity measures more than offset higher tariffs and cost inflation. Monitoring delivered mid-single-digit growth driven by North America and Europe, while Sleep & Respiratory Care posted low-single-digit growth led by Europe and Japan. Enterprise Informatics experienced a mid-single-digit decline as strength in international regions was primarily offset by North America.
The segment strengthened its position as a strategic partner of choice for healthcare providers through several major agreements, as shown in the following overview:
Notable partnerships included a multi-year agreement to standardize monitoring across 50+ hospitals in the U.S., selection for Region Stockholm’s first region-wide hospital-at-home initiative led by Karolinska University Hospital, a 10-year enterprise imaging strategic partnership in the U.S. to deliver a cloud-based imaging ecosystem, and an extended partnership with Imperial College Healthcare NHS Trust in London marking the first full-cloud PACS deployment in Europe.
Personal Health
Personal Health emerged as the fastest-growing segment with sales of EUR 909 million and 8% comparable growth, accelerating from 6% in the prior year.
The segment’s adjusted EBITA margin reached 23.0%, up significantly from 15.2% in Q2 2025. Excluding the tariff refund benefit, the underlying margin stood at 18.0%, expanding through sales growth, productivity measures, and favorable mix that partly offset cost inflation. All three businesses within Personal Health grew, with performance led by North America while China benefited from an easier comparison base.
The segment’s momentum was driven by broad-based strength across its portfolio and successful new product launches, as illustrated in the following overview:
Philips Sonicare platforms and Avent products maintained strong market positions, with the Lumea IPL Hair Removal 9000 Series and Sonicare 6400 winning Good Housekeeping 2026 Beauty Awards. The company launched the S800 series Compact Shaver in China, powered by the revolutionary TurboMax motor delivering up to 5 million cuts per minute for outstanding clean shave performance, available in four colors targeting different consumer preferences.
Financial Analysis
The following summary presents consolidated group financial performance for the quarter:
Total sales reached EUR 4,360 million with 4% comparable growth across all three segments. Personal Health led growth, while Europe showed particular strength and North America remained resilient. The adjusted EBITA margin of 16.4% represented a 400 basis point improvement including the tariff refund, though the underlying margin of 12.2% declined 20 basis points as expected. Importantly, in the first half of 2026, the underlying margin expanded 10 basis points, demonstrating progress toward full-year objectives.
Free cash flow of EUR 222 million was broadly in line with the prior year, as higher working capital outflows were largely offset by the U.S. tariff refund. The leverage ratio improved from 2.2x to 1.8x on a net debt to adjusted EBITDA basis, strengthening the balance sheet.
The following waterfall chart breaks down the key drivers of adjusted EBITA margin performance:
Starting from the Q2 2025 margin of 12.4%, volume, business mix, and innovation contributed 0.8 percentage points, while productivity and pricing added 2.0 percentage points. However, cost inflation and tariffs created a 3.0 percentage point headwind, resulting in an underlying margin of 12.2% before the 4.2 percentage point benefit from the U.S. tariff refund, which brought the reported margin to 16.4%.
Strategic Initiatives
Philips’ productivity program remains on track to deliver EUR 1.5 billion in savings from 2026 through 2028. The following breakdown shows progress and focus areas:
The company delivered EUR 132 million in savings during Q2 2026 and EUR 258 million year-to-date through three main initiatives. Cost competitiveness efforts under Project Synchronize focus on platform and SKU optimization to lower costs, unlock R&D capacity, and improve quality and supply chain reliability. Lean enabling functions through the Simplify to Perform program aim to operate central functions at best-in-class cost benchmark levels while implementing AI-enabled efficiencies in marketing, R&D, and services. Tariff mitigation strategies include accelerating targeted regionalization and supplier and network optimization to fully mitigate currently known tariff impacts by the end of 2028.
Working capital management showed mixed results across segments, as illustrated in the following quarterly trends:
Group working capital increased to approximately EUR 1,800 million or 10.8% of last twelve months’ sales in Q2 2026, up from 9.9% in Q1 2026 but below the 11.9% level in Q2 2025. Group inventories rose to approximately EUR 2,900 million or 18.2% of sales, reflecting supply chain positioning for tariff mitigation and anticipated demand. Diagnosis & Treatment working capital improved to 9.6% of sales from 12.6% in the prior year, while Connected Care increased to 17.3% from 16.0%, and Personal Health rose to 4.9% from 4.4%.
The company’s debt position remained well-structured with no near-term refinancing pressure, as shown in the following maturity profile:
Total net debt stood at EUR 5.7 billion with maturities extending to 2042 and an average tenor of long-term debt of 6.0 years. The debt structure includes no financial covenants and EUR 1 billion of committed credit facilities. Significant maturities include approximately EUR 0.9 billion in 2027, EUR 1.0 billion in 2030, and smaller amounts distributed across subsequent years through 2042, with substantial un-utilized standby facilities providing financial flexibility.
Forward-Looking Statements
Philips raised its full-year 2026 outlook to reflect the U.S. tariff refund benefit while reiterating underlying guidance, as detailed in the following comprehensive outlook:
The company maintained its comparable sales growth outlook of 3% to 4.5%, with all business segments expected to grow within this range. Diagnosis & Treatment is projected at the lower end, while Connected Care and Personal Health are expected at the upper end. Growth will be led by North America and international regions, with Greater China sales expected to be broadly stable. All four quarters are expected to fall within the full-year range, with Q3 at the lower end.
The adjusted EBITA margin outlook increased to 13.5%-14.0% including the tariff refund, or 12.5%-13.0% excluding it, up from the previous underlying guidance. Management expects expansion driven by sales growth, innovation, favorable mix effects, and productivity, though annualized tariffs and input cost inflation will create headwinds. Mitigation actions are expected to increase during the second half through supply chain optimization, cost discipline, and selective pricing. Importantly, Q3 margins are expected to be lower than the prior year before a stronger Q4 finish.
Free cash flow guidance rose to EUR 1.5-1.7 billion including the tariff refund, or EUR 1.3-1.5 billion excluding it, supported by higher earnings and lower adjusting items, partly offset by targeted increases in capital expenditure related to selective localization, multi-modality manufacturing, and tax optimization.
The outlook includes currently known tariffs, which management noted are more favorable than assumed in February 2026 when the company expected annualized tariffs of EUR 250-300 million net of substantial mitigations. The outlook excludes ongoing Philips Respironics related proceedings.
Risks and Challenges
Despite the positive operational performance, several headwinds tempered investor enthusiasm. Cost inflation is running at high-single-digit rates for 2026, creating sustained margin pressure. China’s centralized procurement system continues to create market turmoil as customers adapt to new processes, with pricing pressure and timing delays affecting equipment sales. The company explicitly cautioned that Q3 margins will be below the prior year due to unfavorable mix and inflation, even as it expects a stronger Q4.
The gap between strong order intake on a rolling twelve-month basis and slower quarterly growth highlights conversion challenges, particularly for large and complex deals in Connected Care and imaging. Management indicated that order intake is expected to return to mid-single-digit growth in Q3 and beyond, suggesting near-term unevenness in commercial momentum.
The market’s negative reaction despite the earnings beat and raised guidance suggests investor concern that the quarter benefited from temporary factors while near-term challenges remain substantial. Trading near 52-week lows indicates that sentiment has not yet turned despite improved leverage ratios and record order books, with investors awaiting evidence of sustained underlying margin improvement and resolution of China market pressures.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.